SciClone Pharmaceuticals, Inc. is a specialty pharmaceutical company with a substantial commercial business in China. Its product portfolio, of nearly 20 drugs sold in over 30 countries, includes therapies for oncology, infectious diseases, and cardiovascular, urological, respiratory, and central nervous system disorders.
The company today announced its anticipated full-year 2011 revenues and cash position. For 2011, SciClone anticipates revenues of approximately $134 million, including revenues from Nova Med Pharmaceuticals which was acquired in April 2011. This figure is a 57% increase over the 2010 level. The cash position as of December 31, 2011 is expected to be $66 million versus $57 million at the end of last year.
SciClone today also gave its initial guidance for revenues and cash position for the full-year 2012. The company expects 2012 sales revenue to come in between $165 million and $170 million. If management is correct, this would represent an approximately 25% increase over 2011. The company also anticipates its year-end cash position to be greater than $85 million, barring any further acquisitions.
The company stated that revenue gains were led by its very successful ZADAXIN product in China. This drug may be used for the treatment of hepatitus B and C, as a vaccine adjuvant, and as a treatment for certain cancers.
SciClone anticipates reporting its complete 2011 financial results and further 2012 guidance in early March. For more information about SciClone Pharmaceuticals, please visit the company’s website at www.sciclone.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
